Anders Hove

Managing Partner at Amzak Capital Management LLC

Anders Hove

Anders Hove

Managing Partner at Amzak Capital Management LLC

Overview
Career Highlights

Amzak Capital Management LLC
Bellevue Asset Management LLC
Bellevue Asset Management

RelSci Relationships

976

Number of Boards

21

Birthday

1966

Age

54

Number of Awards

1

Relationships
RelSci Relationships are individuals Anders Hove likely has professional access to. A relationship does not necessarily indicate a personal connection.

Managing Partner, Life Sciences Team at Frazier Healthcare Partners

Relationship likelihood: Strong

Partner at Venrock Associates

Relationship likelihood: Strong

Former Director, President & Chief Executive Officer at PDS Biotechnology Corp.

Relationship likelihood: Strong

Managing Partner at Amzak Capital Management LLC

Relationship likelihood: Strong

General Counsel at Venrock Associates

Relationship likelihood: Strong

Chief Financial Officer at VR Adviser LLC

Relationship likelihood: Strong

Partner at Venrock Associates

Relationship likelihood: Strong

Partner at Venrock Associates

Relationship likelihood: Strong

Partner at Aisling Capital

Relationship likelihood: Strong

Former Chief Executive Officer & Director at PDL BioPharma, Inc.

Relationship likelihood: Strong

Paths to Anders Hove
Potential Connections via
Relationship Science
You
Anders Hove
Managing Partner at Amzak Capital Management LLC
Education
MSc in Biotechnology Engineering

For almost two centuries DTU, Technical University of Denmark, has been dedicated to fulfilling the vision of H.C. Ørsted – the father of electromagnetism – who founded the university in 1829 to develop and create value using the natural sciences and the technical sciences to benefit society. Today, DTU is ranked as one of the foremost technical universities in Europe, continues to set new records in the number of publications, and persistently increase and develop our partnerships with industry, and assignments accomplished by DTU’s public sector consultancy.

M.B.A.

INSEAD is a graduate business school with campuses in Europe, Asia and the Middle East. INSEAD, widely considered one of the best business schools in the world, allows its students to study in the US (West Coast- San Francisco via Wharton exchange, East Coast- Philadelphia via Wharton exchange, Midwest- Evanston near Chicago via Kellogg exchange), in Asia (Singapore via INSEAD Asia Campus exchange and Shanghai via CEIBS exchange), in the Middle East (Abu Dhabi via INSEAD Middle East Campus exchange) and in Europe (Fontainebleau via INSEAD Europe Campus exchange)

MD Unknown

With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark. The purpose of the University – to quote the University Statute – is to ’conduct research and provide further education to the highest academic level’.

Career History
Chief Executive Officer
1996 - 2004

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm's in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech's investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Asset Manager
2002 - 2003

The Group's principal activity is the management of portfolio investments in companies active in the health care industry.

Partner
2004 - Prior

Venrock helps entrepreneurs build some of the world's most disruptive, successful companies. They partner with entrepreneurs who have grand ambitions and help's them in almost every dimension of building their company: hiring, strategy, financing, scaling, introductions and managing a great exit. The firm targets to invest in companies operating in the fields of technology & health care sectors and provides financing for early stage capital requirements.

Boards & Committees
Independent Director
2017 - Current

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Director
2007 - Current

QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI.

Member, Board of Directors
Current

Venrock Healthcare Capital Partners II LP invests in companies located in the US. The fund focuses on companies operating in the fields of information technology and healthcare. It provides financing for seed and early stage capital requirements.

Member, Health Care Advisory Board
Current

The Partnership Fund for New York City was founded by Henry R. Kravis and capitalized by leaders of global business and finance. Established in 1996, the Fund operates as the economic development extension of Partnership NYC, the leading voice for New York’s business community. Each of our sixty-seven initial investors contributed $1 million to capitalize the fund for the benefit of New York City, and without expectation of financial return. To date, the Partnership Fund has invested in over 100 exemplary projects that have made and continue to make meaningful impact in local economic growth.

Political Donations
$2,500
2013
$2,500
2012
$2,500
2011
Investments
Details Hidden

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

Details Hidden

Monogram Biosciences, Inc. develops and commercializes diagnostic products for the treatment of human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, and other viral illnesses, as well as cancer and other diseases. It offers HIV tests, including genotypic, phenotypic, tropism, and combined phenotype/genotype assays, as well as suppression management and viral load testing, HCV assays and oncology tests. The company was founded in 1995 and is headquartered in South San Francisco, CA.

Details Hidden

Third Wave Technologies, Inc. developed DNA and RNA detection technology. It provided molecular solutions for clinical, research, and agricultural customers. The company was founded in February 1993 and was headquartered in Madison, WI.

Awards & Honors
Rank #97
2011
Forbes Magazine - The Midas List
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Anders Hove. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Anders Hove's profile does not indicate a business or promotional relationship of any kind between RelSci and Anders Hove.